Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A prospective, multicentre, open-label, randomized, phase 2-3 study to compare the efficacy
and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic
acid) versus Best Supportive Care, in third or fourth line treatment of patients with
metastatic colorectal cancer